| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 01/03/2002 | US20020001631 Human growth hormone |
| 01/03/2002 | DE10030375A1 Verwendung von MTP-Inhibitoren zur Senkung von ppTRL Use of MTP inhibitors to reduce ppTRL |
| 01/03/2002 | DE10029371A1 Heterocyclische Aminoalkylpyridinderivate als Psychopharmaka Heterocyclic Aminoalkylpyridinderivate as psychotropic drugs |
| 01/03/2002 | DE10027514A1 Liganden von Integrinrezeptoren Ligands of integrin |
| 01/03/2002 | CA2413683A1 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | CA2413547A1 B7-like molecules and uses thereof |
| 01/03/2002 | CA2413417A1 Selective androgen receptor modulators and methods for their identification, design and use |
| 01/03/2002 | CA2413301A1 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | CA2412610A1 Gp286 nucleic acids and polypeptides |
| 01/02/2002 | EP1167385A2 Human follicle stimulating hormone receptor |
| 01/02/2002 | EP1165789A2 Vesicle associated proteins |
| 01/02/2002 | EP1165784A2 Nucleic acids including open reading frames encoding polypeptides; "orfx" |
| 01/02/2002 | EP1165761A2 Methods for altering substrate specificity of phosphoinositide-dependent-protein kinase 1 (pdk1) |
| 01/02/2002 | EP1165613A1 Melanocortin receptor ligands |
| 01/02/2002 | EP1165612A2 A method for purifying human growth hormone |
| 01/02/2002 | EP1165606A1 50 human secreted proteins |
| 01/02/2002 | EP1165595A1 Liver specific bile acid derivatives of the glucocorticoid antagonist ru486 |
| 01/02/2002 | EP1165537A1 Hydroxymatairesinol in cancer prevention |
| 01/02/2002 | EP1165502A1 Diaryl derivatives and their use as medicaments |
| 01/02/2002 | EP1165183A1 Low dose estrogen interrupted hormone replacement therapy |
| 01/02/2002 | EP1165113A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |
| 01/02/2002 | EP1165076A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/02/2002 | EP1165075A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/02/2002 | EP1165055A2 Pharmaceutical composition containing an extrusion additive |
| 01/02/2002 | EP1164991A1 Gels formed by the interaction of poly(aldehyde) with various substances |
| 01/02/2002 | CN1329620A Analogues of GLP-1 |
| 01/02/2002 | CN1329485A Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period |
| 01/02/2002 | CN1328824A Compound for curing female sexual disorder |
| 01/01/2002 | US6335327 1-benzazepine derivatives; agonists or antagonists of vasopressin and/or oxytocin |
| 01/01/2002 | CA2171939C Novel method of progesterone delivery and affect thereof |
| 12/29/2001 | CA2351897A1 Use of growth hormone secretagogues for treatment of physical performance decline |
| 12/27/2001 | WO2001098493A1 Insulin-like growth factor-binding protein |
| 12/27/2001 | WO2001098354A2 Human receptors |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098346A2 Methods and compositions for the treatment of peripheral artery disease |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098295A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them |
| 12/27/2001 | WO2001098293A1 Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals |
| 12/27/2001 | WO2001098289A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | WO2001098277A2 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 12/27/2001 | WO2001098256A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones |
| 12/27/2001 | WO2001097787A2 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl) |
| 12/27/2001 | WO2000064485A3 Specifically targeted catalytic antagonists and uses thereof |
| 12/27/2001 | US20010056179 Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity |
| 12/27/2001 | US20010056099 Method of reducing morbidity and the risk of mortality |
| 12/27/2001 | US20010055625 Herbal composition and method of manufacturing such composition for the management of gynecological disorders |
| 12/27/2001 | CA2414020A1 Methods and compositions for the treatment of peripheral artery disease |
| 12/27/2001 | CA2414015A1 Human receptors |
| 12/27/2001 | CA2414010A1 Secreted redox proteins |
| 12/27/2001 | CA2413277A1 Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl) |
| 12/27/2001 | CA2411585A1 Novel non-psychotropic cannabinoids |
| 12/27/2001 | CA2409778A1 Secreted proteins |
| 12/26/2001 | CN1328570A Antagonistic analogs in GH-RH inhibiting IGF-I and -II |
| 12/26/2001 | CN1328559A CRF receptor antagonists and methods relating thereto |
| 12/26/2001 | CN1328552A Pyrimidone derivatives |
| 12/26/2001 | CN1328538A 2,4-pentadienoic acid derivatives having selective activity for retinoid X(RXR) receptors |
| 12/26/2001 | CN1328452A Use of benzoylguanidines for treatment of non-insulin-dependent diabetes mellitus |
| 12/26/2001 | CN1327808A Hualin Plaster for treating thyrome and its preparing process and prescription |
| 12/26/2001 | CN1076624C Nasally administrable compositions |
| 12/25/2001 | CA2018714C Hypothalamic polypeptides with adenylate cyclase stimulating activity |
| 12/20/2001 | WO2001096565A2 Binding agents: chimeric ligand/receptor proteins |
| 12/20/2001 | WO2001096547A2 Human kinases |
| 12/20/2001 | WO2001096546A2 Protein phosphatases |
| 12/20/2001 | WO2001096331A1 Lactam inhibitors of factor xa and method |
| 12/20/2001 | WO2001096302A1 Piperidines for use as orexin receptor antagonists |
| 12/20/2001 | WO2001096300A1 Growth hormone secretagogues |
| 12/20/2001 | WO2001095928A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | WO2001095890A2 Oral pharmaceutical compositions containing terbinafine |
| 12/20/2001 | WO2001095888A1 Bioadhesive progressive hydration tablets |
| 12/20/2001 | WO2001095859A2 Novel heterocyclic analogs of diphenylethylene compounds |
| 12/20/2001 | WO2001095711A2 Transgenic mice containing nuclear hormone receptor gene disruptions |
| 12/20/2001 | WO2001085197A8 Method for curing diffusive masthopaty |
| 12/20/2001 | WO2001019770A3 Rxr modulators with improved pharmacologic profile |
| 12/20/2001 | WO2001016108A3 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 12/20/2001 | US20010053363 Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors |
| 12/20/2001 | CA2412216A1 Lactam inhibitors of factor xa and method |
| 12/20/2001 | CA2411962A1 Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | CA2410659A1 Transgenic mice containing nuclear hormone receptor gene disruptions |
| 12/20/2001 | CA2410610A1 Human kinases |
| 12/20/2001 | CA2410171A1 Novel heterocyclic analogs of diphenylethylene compounds and uses thereof |
| 12/20/2001 | CA2409315A1 Protein phosphatases |
| 12/19/2001 | EP1163902A2 Transdermal preparation containing hydrophilic or salt-form drug |
| 12/19/2001 | EP1163356A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites |
| 12/19/2001 | EP1163264A1 Novel lhrh antagonists with improved solubility characteristics |
| 12/19/2001 | EP1163259A1 14.beta.,17-alpha-hydroxymethylandrostane derivatives as androgens |
| 12/19/2001 | EP1163254A2 Trpm-2 antisense therapy |
| 12/19/2001 | EP1163244A1 Thienopyrimidine compounds, their production and use |
| 12/19/2001 | EP1163238A1 Chemokine recpetor binding heterocyclic compounds |
| 12/19/2001 | EP1163233A1 Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use |
| 12/19/2001 | EP1163225A1 Compounds and methods for modulation of estrogen receptors |
| 12/19/2001 | EP1163212A1 Amide derivatives |
| 12/19/2001 | EP1163208A2 Caspase inhibitors and uses thereof |
| 12/19/2001 | EP1162979A2 Cyclic glycerophosphates and analogs thereof |
| 12/19/2001 | CN1326928A Biphenyl sulfonyl amino-cyanogen, its preparing method and use as medicine thereof |
| 12/18/2001 | US6331642 Vitamin D3 analogs |
| 12/18/2001 | US6331615 Nucleic acid molecule encoding heavy or light chain of an antibody which specifically recognizes a protein specifically recognized by monoclonal antibody 5c8 (anti-CD40 ligand) |
| 12/18/2001 | US6331520 Luteinizing hormone releasing hormone peptide agonist or antagonist; or growth hormone releasing factor peptide; nicontinamide aqueous solution |
| 12/18/2001 | US6331433 Human T cell leukemia cell line designated D1.1 |
| 12/18/2001 | CA2209298C Mpl ligand analogs |
| 12/13/2001 | WO2001094636A2 Compositions, kits, and methods for identification and modulation of type i diabetes |